Maternal exposure to sleep aids and risk of specific birth defects in the Birth Defects Study To Evaluate Pregnancy exposureS.

STUDY OBJECTIVES: Insomnia symptoms are often reported during pregnancy, prompting use of pharmacologic treatments. We explored associations between treatments used during the month before through the third month of pregnancy ("early pregnancy") and risk of birth defects using Birth Defects Study to Evaluate Pregnancy exposureS (BD-STEPS) data from 2014-2021. METHODS: Pregnancies affected by birth defects ("cases") were identified from surveillance systems in seven states; liveborn infants without birth defects ("controls") were randomly selected from the same catchment areas. Mothers of cases and controls reported early pregnancy exposures via interview, including use of prescription, over-the-counter, or herbal sleep aids. For defects with ≥5 exposed cases, we used Firth's logistic regression to estimate propensity score-adjusted odds ratios (aORs) and 95% confidence intervals (CIs), adjusting for maternal age, race/ethnicity, education, body mass index, previous live birth, history of depression/anxiety, early pregnancy use of antipsychotics, anxiolytics, antidepressants, opioids, cigarettes, alcohol, and prenatal vitamins, occurrence of stressful events, occupation outside the home, health insurance, and site. RESULTS: Overall, 237 (7%) cases and 140 (8%) controls reported early pregnancy sleep aid use. We calculated aORs for 12/22 defects, which ranged from 0.52 for d-transposition of the great arteries to 1.61 for coarctation of the aorta. All CIs included the null. CONCLUSIONS: Results suggest sleep aids do not increase risk of most defects studied, but increased risk for coarctation of the aorta cannot be ruled out. Small numbers limited analyses. Studies examining the severity of underlying sleep disorders and impacts of specific sleep aids would be beneficial.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-11-12
DOI
https://doi.org/10.1093/sleep/zsag297
Primary Topic
Pregnancy and Medication Impact
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Maternal exposure to sleep aids and risk of specific birth defects in the Birth Defects Study To Evaluate Pregnancy exposureS.

Melissa Tracy, Elizabeth C. Ailes, Eva M. Williford, Sarah C. Fisher et al.
PubMed
Pregnancy and Medication Impact
article

Maternal exposure to sleep aids and risk of specific birth defects in the Birth Defects Study To Evaluate Pregnancy exposureS.

Melissa Tracy, Elizabeth C. Ailes, Eva M. Williford, Sarah C. Fisher, Eleni A. Papadopoulos, Jennita Reefhuis, Meredith M. Howley, Martha M. Werler
article en

Abstract

STUDY OBJECTIVES: Insomnia symptoms are often reported during pregnancy, prompting use of pharmacologic treatments. We explored associations between treatments used during the month before through the third month of pregnancy ("early pregnancy") and risk of birth defects using Birth Defects Study to Evaluate Pregnancy exposureS (BD-STEPS) data from 2014-2021. METHODS: Pregnancies affected by birth defects ("cases") were identified from surveillance systems in seven states; liveborn infants without birth defects ("controls") were randomly selected from the same catchment areas. Mothers of cases and controls reported early pregnancy exposures via interview, including use of prescription, over-the-counter, or herbal sleep aids. For defects with ≥5 exposed cases, we used Firth's logistic regression to estimate propensity score-adjusted odds ratios (aORs) and 95% confidence intervals (CIs), adjusting for maternal age, race/ethnicity, education, body mass index, previous live birth, history of depression/anxiety, early pregnancy use of antipsychotics, anxiolytics, antidepressants, opioids, cigarettes, alcohol, and prenatal vitamins, occurrence of stressful events, occupation outside the home, health insurance, and site. RESULTS: Overall, 237 (7%) cases and 140 (8%) controls reported early pregnancy sleep aid use. We calculated aORs for 12/22 defects, which ranged from 0.52 for d-transposition of the great arteries to 1.61 for coarctation of the aorta. All CIs included the null. CONCLUSIONS: Results suggest sleep aids do not increase risk of most defects studied, but increased risk for coarctation of the aorta cannot be ruled out. Small numbers limited analyses. Studies examining the severity of underlying sleep disorders and impacts of specific sleep aids would be beneficial.

PubMed
Boston University (US), Centers for Disease Control and Prevention (US), New York State Department of Health (US), University at Albany, State University of New York (US), National Center on Birth Defects and Developmental Disabilities (US)
Good health and well-being
Pregnancy and Medication Impact
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon